Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Middle East Conflict Impacts Australia and New Zealand Businesses 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
BEVERLY, Mass. and TORONTO, May 01, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne Ltd., will present at the 2018 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Hotel Toronto on Thursday May 3, 2018 at 11:00 a.m. Eastern Time.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly
traded and private companies through presentations and private meetings.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Glen Akselrod
Bristol Investor Relations
905-326-1888
[email protected]
